Briggs Morrison, the executive vice president for R&D at AstraZeneca ($AZN) and a major player in the pharma company's turnaround attempt over the past three years, is leaving the pharma giant and taking the helm of a private pharma company, FierceBiotech has learned.
Staffers were buzzing this morning that Morrison's abrupt departure was left unexplained, as CEO Pascal Soriot spread the word that he would be stepping in to run late-stage R&D in the interim. A spokesperson confirmed the exit this morning, saying that colleagues were notified earlier today.
According to AstraZeneca, Morrison is taking a job as CEO of a "small, privately-held pharmaceutical company." A spokesperson declined to name the company and Morrison did not immediately return a message from FierceBiotech. "It's a great opportunity for him," she added. Soriot will take on Morrison's responsibilities as chief medical officer in charge of global development at AstraZeneca until a successor is named.
http://www.fiercebiotech.com/story/astrazeneca-rd-chief-briggs-morrison-makes-unexpected-exit/2015-06-10?utm_medium=rss&utm_source=feedly&utm_campaign=rss
No comments:
Post a Comment